Propanc Biopharma, Inc.

COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

RECENT NEWS

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
Feb 18 2026, 8:45 AM EST

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
Feb 5 2026, 8:45 AM EST

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
Jan 27 2026, 8:45 AM EST

STOCK OVERVIEW

Symbol	PPCB
Exchange	Nasdaq
Market Cap	2.89m
Last Price	$0.1821
52-Week Range	$0.1555 - $11.00

03/02/2026 09:00 PM EST

INVESTOR RELATIONS

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

MANAGEMENT TEAM

James Nathanielsz
CEO and Executive Chairman

Prof. Dr. Klaus Kutz
Chief Medical Officer

Dr. Ralf Brandt
Research & Development Director

Jeannine Zimmerman
Chief Financial Officer

PROPANC BIOPHARMA, INC.

302/6 Butler Street
Camberwell, VIC 3124
AU

DISCLAIMER